My SciELO
Services on Demand
Article
Indicators
- Cited by SciELO
Related links
- Similars in SciELO
Share
Revista Cubana de Hematología, Inmunología y Hemoterapia
On-line version ISSN 1561-2996
Abstract
FERNANDEZ DELGADO, Norma and HERNANDEZ RAMIREZ, Porfirio. Myelodysplastic syndrome: I. Biology and Clinic. Rev Cubana Hematol Inmunol Hemoter [online]. 2000, vol.16, n.1, pp. 5-20. ISSN 1561-2996.
Myelodysplastic syndromes (MDS) include a group of clonic disorders characterized by progressive cytopenias and dishematopoiesis. Etiology of primary MDS is unknow, and secondary ones may be due to use of antineoplastic agents, chemicals and in children, are related to constitutional diseases. Their general biological features include cytogenetic, molecular, and immunologic alterations accompaning hematopoiesis alterations. For diagnosis it is necessary 10% of cellular involvement in each serie, where dishematopoiesis be the cause. In 80% of bone marrow biopsies, we found signs of dismegacaryopoiesis and disarrangement in normal hematopoietic structure. Recently, it was proposed existence of MDS variants, including hyperfibrotic type, the early one, and MDS with features of myeloproliferative syndrome. Diagnosis of MDS is by exclusion and in differential diagnosis, it is necessary rule out some processes presenting myelodisplastic alterations, including anemias by vitamin B12, folic acid, or piridoxin deficiency, chronic liver disease, chronic diseases anemia, chemotherapy, AIDS virus infection, and medullary aplasia, etc
Keywords : MYELODYSPLASTIC SYNDROMES; ANTINEOPLASTIC AGENTS; MYELOPROLIFERATIVE DISORDERS; VITAMIN B12 DEFICIENCY.